Storage Condition
Store at refrigerator (2-8°C) for long term storage
Synonyms
3-(6-(1-(2,2-Difluorobenzo[d][1,3]dioxol-5-yl)cyclopropane-1-carboxamido-2,2,3,3-d4)-3-methylpyridin-2-yl)benzoic Acid
Application Notes
Useful research chemical for a range of applications
Purity by HPLC
Not less than 90%
Hazard Compound
No -Refer MSDS for accurate information
Lumacaftor-d4 is a drug product that is used as an analytical standard for HPLC, as well as in research and development of drugs.
Refund Policy
We are committed to offering products of the highest quality in order to meet the needs of our customers, and have elaborate systems in
place to ensure that material specifications, their certification and all handling and storage conditions are communicated at the time of
material handover.
We have invested in the highest quality packaging materials and use international logistics partners to service our customers. While all
possible precautions have been taken to deliver the required product(s), there may be some rare situations when our product does not
meet your requirements. Should that arise, please contact us with your concerns and we will endeavour to address them on a priority
basis. If there is no other option, we will either replace your product(s) or issue a refund or account credit, whichever you prefer.
If there is an issue with one or more of our products, our policy is that it must be reported to us within 45 days of your receiving shipment.
While we will always address product issues after the 45 day return window has passed, we cannot issue a refund or account credit. As
always, we appreciate your support.
Lumacaftor-d4 usage and description
Lumacaftor D4 is a chemical compound that is used in the treatment of cystic fibrosis. It is a derivative of Lumacaftor, which is an approved drug for treating cystic fibrosis. Lumacaftor D4 is essentially a labeled version of Lumacaftor, where the hydrogen atoms on the fourth carbon of the cyclohexane ring are replaced with deuterium atoms. This labeling allows for pharmacokinetic studies to be conducted on the compound, which can provide insights into the drug's mechanism of action, distribution, and elimination from the body.
Lumacaftor D4 is administered orally in the form of tablets. It works by increasing the amount of functional CFTR (cystic fibrosis transmembrane conductance regulator) protein in the body. CFTR is a protein that regulates the transport of salt and water in and out of cells. In individuals with cystic fibrosis, the CFTR protein is either absent or dysfunctional, leading to thick and sticky mucus in the lungs, pancreas, and other organs.
The labeling of Lumacaftor D4 with deuterium atoms does not alter the drug's therapeutic properties or safety. However, it does allow for more precise monitoring of the drug's distribution and elimination from the body. This information can be used to optimize dosing regimens, improve drug efficacy, and minimize adverse effects. In conclusion, Lumacaftor D4 is a valuable tool in the study of cystic fibrosis and the development of new treatments for this debilitating disease.
